BDRX Key Statistics, Chart & Performance
The current stock price of BDRX is 2.46 USD. In the past month the price decreased by -49.9%. In the past year, price decreased by -94.53%.
BDRX Latest News, Press Relases and Analysis
BDRX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About BDRX
Company Profile
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 13 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
Company Info
BIODEXA PHARMACEUTICALS-ADR
1 Caspian Point, Caspian Way
Abingdon OXFORDSHIRE GB
Employees: 13
Phone: 4401235888300
BIODEXA PHARMACEUTICALS-ADR / BDRX FAQ
What does BDRX do?
Biodexa Pharmaceuticals Plc is a drug delivery technology company. The company is headquartered in Abingdon, Oxfordshire and currently employs 13 full-time employees. The company went IPO on 2014-12-08. The firm is developing a pipeline of products for the treatment of diseases with unmet medical needs. The Company’s lead development program, eRapa, is under development for familial adenomatous polyposis and non-muscle invasive bladder cancer; tolimidone, under development as a for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare/orphan brain cancer indications, including recurrent glioblastoma, diffuse midline glioma, or DMG, and medulloblastoma. Its technologies include Q-Sphera, MidaCore and MidaSolve. The Q-Sphera platform is a polymer microsphere microtechnology used for sustained delivery to prolong and control the release of therapeutics over an extended period of time, from weeks to months. Its MidaSolve platform is an oligosaccharide nanotechnology that is used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors.
What is the stock price of BIODEXA PHARMACEUTICALS-ADR today?
The current stock price of BDRX is 2.46 USD. The price increased by 8.37% in the last trading session.
Does BDRX stock pay dividends?
BDRX does not pay a dividend.
What is the ChartMill rating of BIODEXA PHARMACEUTICALS-ADR stock?
BDRX has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of BIODEXA PHARMACEUTICALS-ADR (BDRX) based on its PE ratio?
BIODEXA PHARMACEUTICALS-ADR (BDRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-28.56).
Would investing in BIODEXA PHARMACEUTICALS-ADR be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on BDRX.
BDRX Technical Analysis
BDRX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BDRX. While BDRX seems to be doing ok healthwise, there are quite some concerns on its profitability.
BDRX Financial Highlights
Over the last trailing twelve months BDRX reported a non-GAAP Earnings per Share(EPS) of -28.56. The EPS increased by 98.57% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -42.01% | ||
| ROE | -54.45% | ||
| Debt/Equity | 0 |
BDRX Forecast & Estimates
7 analysts have analysed BDRX and the average price target is 183.6 USD. This implies a price increase of 7363.41% is expected in the next year compared to the current price of 2.46.